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ABSTRACT
Autophagy and apoptosis are 2 stress-response mechanisms that are closely interconnected. However, the
molecular interplays between these 2 pathways remain to be clarified. Here we report that the crucial
proautophagic factor AMBRA1 can act as a positive mediator of mitochondrial apoptosis. Indeed, we show
that, in a proapoptotic positive feedback loop, the C-terminal part of AMBRA1, generated by CASP/
CASPASE cleavage upon apoptosis induction, inhibits the antiapoptotic factor BCL2 by a direct binding
through its BH3-like domain. The mitochondrial AMBRA1-BCL2 complex is thus at the crossroad between
autophagy and cell death and may represent a novel target in development of therapeutic approaches in
clinical diseases.
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Introduction
Autophagy is an important eukaryotic process involved in the
lysosomal degradation of cytosolic components, both under
physiological and pathological conditions. During autophagy,
the autophagosomes—specific double-membrane vesicles—
engulf a number of different cargoes and then fuse with lyso-
somes for subsequent recycling of their content. Several key
proteins are involved in autophagosome formation, such as
BECN1/Beclin 1 and its positive regulator AMBRA1; AMBRA1
and BECN1 are present in the class III phosphatidylinositol 3-
kinase (PtdIns3K) complex,1,2 and are involved in autophago-
some nucleation, an early step of autophagy induction. More
recently, it has been demonstrated that AMBRA1 and BECN1
can also regulate autophagy at different steps of the process, by
binding other key interactors.3-6 Interestingly, a pool of
AMBRA1 is localized at the mitochondria, where its proauto-
phagic activity is inhibited by mitochondrial resident BCL2.7
Moreover, AMBRA1 regulates mitophagy, a form of autophagy
that ensures the specific removal of damaged mitochondria,
both dependently or independently of the E3-ubiquitin Ligase
PARK2/PARKIN.8
The fact that AMBRA1 interacts with the antiapoptotic factor
BCL2 places it at the crossroad between autophagy and cell death.
In fact, BCL2, a well-known antiapoptotic factor whose overex-
pression protects against a wide range of apoptotic inducers, can
regulate BECN1-induced autophagy at the endoplasmic reticu-
lum by a direct binding to the BECN1 BH3 domain and with the
contribution of CISD2/NAF-1 (CDGSH iron sulfur domain
2).9,10 BCL2 can also regulate BECN1-induced autophagy by
sequestering AMBRA1 (the activator of BECN1) at the mito-
chondria.6 Conversely, it has been demonstrated that a number
of regulators of autophagy, such as BECN1 and PI3K3C3/
Vps34,11,12,13,14,15 ATG4A/ATG4, ATG5,16,17,18,19 or AMBRA1,20
are subjected to proteolytic cleavage during cell death so as to
abrogate their proautophagic function. Another point of conver-
gence between autophagy and apoptosis is the binding between
ATG12 and BCL2 family members that takes place in order to
induce mitochondrial apoptosis.21
Besides AMBRA1 binding to BCL2 in the mitochondrial
fraction, we have previously demonstrated that this event is
reduced following apoptosis induction,7 this indicating that
AMBRA1 could be involved in cell death regulation.
In this work, we explore the relationship between
AMBRA1 and the death machinery by investigating whether
AMBRA1 could disrupt BCL2’s ability to protect against apo-
ptosis. In particular, because AMBRA1 is cleaved by CASP
during apoptosis, we decided to study the effect of the C-ter-
minal fragment of AMBRA1, which is released by this CASP
cleavage, on BCL2. We found that this fragment, through a
BH3-like domain, is able to inhibit the antiapoptotic function
of BCL2 so as to enhance apoptosis. To summarize, we pro-
pose a model in which AMBRA1 is involved in both autoph-
agy and apoptosis, depending upon the presence of its full-
length or cleaved form.
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Results
To test whether AMBRA1 could have an effect on BCL2 antia-
poptotic functions, we first cotransfected HEK293 cells with a
vector encoding AMBRA1 and a vector encoding mito-BCL2, a
mutant of BCL2 which have a mitochondria-restricted subcel-
lular localization and which is known to interact with
AMBRA1.7 We next measured cell viability following treatment
with staurosporin (STS), a pan-kinase inhibitor commonly
used to induce rapid activation of mitochondrial apoptosis.
However, surprisingly, when AMBRA1 was cotransfected
together with mito-BCL2, this protective effect was lost
(Fig. 1A). This result was also observed by counting pyknotic
nuclei in transfected cells (Fig. S1A). To elucidate the action of
AMBRA1 on the protective effect of mito-BCL2, we performed
a western blot analysis for the cleavage of PARP1 (fragment of
89 kDa), a CASP substrate. Again, cotransfection of AMBRA1
with mito-BCL2 abrogates this protective effect (Fig. 1B).
Next, we decided to investigate CYCS/cytochrome C release
from mitochondria, another crucial step during apoptosis
induction. To this end, we performed a confocal microscopy
analysis on HEK293 cells cotransfected with a vector encoding
mito-DsRED used in order to stain mitochondria (this vector
contains a mitochondria targeting sequence fused with Ds-
RED protein) , and with AMBRA1 alone, mito-BCL2 alone or
the 2 constructs together. As expected, mito-BCL2 overexpres-
sion was able to reduce CYCS release from mitochondria, as
shown by an almost complete overlap between mitochondria
(red staining) and CYCS (green staining) (Fig. 1C). However,
the merging between mitochondria and CYCS was completely
lost in cells overexpressing both AMBRA1 and mito-BCL2, so
indicating a stronger release of CYCS in these cells. Quantifica-
tion of CYCS release from mitochondria confirms that the
BCL2 antiapoptotic effect is abolished when AMBRA1 is
cotransfected with BCL2 (Fig. 1D). Overall, these results indi-
cate that AMBRA1, in combination with mito-BCL2, may exert
a proapoptotic activity.
Pagliarini et al. have previously demonstrated that AMBRA1
is subjected to proteolytic cleavage during apoptosis,20 which
leads to generation of 2 protein fragments. Of note, the C-ter-
minal part of the protein proves to be more stable than the
N-terminal fragment, which, instead, undergoes rapid degrada-
tion. Based on this finding, we thus hypothesized that one pos-
sible way by which AMBRA1 could regulate the BCL2
antiapoptotic effect, is via its C-terminal part (generated after
CASP cleavage).
First, in order to test this hypothesis, we decided to investi-
gate whether AMBRA1’s C-terminal fragment (AMBRA1CT),
resulting from CASP cleavage, interacted with BCL2 during cell
death. To answer this question, endogenous proteins extracted
from HEK293 cells treated with DMSO (as control) or with
STS were analyzed by size-exclusion fast protein liquid chroma-
tography (sec-FPLC). The collected protein fractions were then
studied by western blot analysis, using specific antibodies
against AMBRA1 and BCL2. As shown in Fig. 2A, AMBRA1
(molecular mass of »130 kDa) is copurified in the same frac-
tion with BCL2 in DMSO conditions (fraction 24). In contrast,
a fragment of AMBRA1 (molecular mass of »100 kDa, only
visible upon staurosporine treatment and likely corresponding
to endogenous AMBRA1CT) and BCL2 are copurified in the
same fractions (fractions 31 to 33, indicated with #), demon-
strating the existence of a macromolecular complex comprising
the 2 proteins, and with a molecular mass of »120 kDa. This
result indicates that the endogenous C-terminal part of
AMBRA1 generated during cell death, as revealed by PARP
cleavage in the given conditions (right panel in Fig. 2A), is in a
macromolecular complex with endogenous BCL2.
Second, to assess BCL2 interaction with AMBRA1CT, we
transfected HEK293 cells with a construct encoding MYC-
tagged AMBRA1 wild-type (AMBRA1WT) or Flag-tagged
AMBRA1CT (Flag-AMBRA1CT). We then treated these cells
with STS in order to induce cell death; we next immunoprecipi-
tated, using an anti-MYC antibody for the AMBRA1WT con-
struct or, with an anti-Flag antibody for the AMBRA1CT
construct, in normal and apoptotic conditions. As shown in
Fig. 2B, BCL2 coimmunoprecipitates with AMBRA1WT in nor-
mal conditions whereas this binding is disrupted following STS
treatment. In contrast, AMBRA1CT coimmunoprecipitatess
with BCL2 with higher affinity both in normal conditions and
following cell death induction. To confirm this result, we per-
formed a confocal microscopy analysis between AMBRA1WT
or AMBRA1CT with endogenous BCL2, in normal conditions
or following STS treatment. As shown in Fig. S1B, endogenous
BCL2 strongly colocalizes with AMBRA1CT following STS
treatment when compared to AMBRA1WT. Interestingly, we
found that cleaved AMBRA1 competes with full-length
AMBRA1 for binding to BCL2 (Fig. S2), suggesting that cleaved
AMBRA1 is more prone to bind BCL2 than full-length
AMBRA1. Since we previously have demonstrated that
AMBRA1 is able to bind the mitochondrial pool of BCL2,6 in
order to verify whether AMBRA1CT was also able to bind the
mitochondrial pool of BCL2, we performed a confocal micros-
copy analysis to check the subcellular distribution of
AMBRA1WT or AMBRA1CT. In order to stain mitochondria,
we overexpressed mito-DsRED with AMBRA1WT or
AMBRA1CT alone (Fig. 2C, top panels) or with both
AMBRA1WT or AMBRA1CT and mito-BCL2 (Fig. 2C, bottom
panels). AMBRA1WT and AMBRA1CT (green staining) are
widely distributed in the cytoplasm, and a partial colocalization
with the mitochondrial network is detected (merged). Of note,
the mitochondrial network (red staining) appears fragmented
following AMBRA1CT overexpression, indicating a putative
proapoptotic effect of AMBRA1CT. More interestingly, we
observed that mito-BCL2 overexpressed together with
AMBRA1CT is sufficient to massively recruit AMBRA1CT on
mitochondria. Forty-eight h post-transfection, cells double-
positive for AMBRA1CT and mito-BCL2 undergo cell death (as
shown by detection of apoptotic nuclei), exhibiting a mitochon-
drial network, which is completely aggregated around the
nucleus (often defined as “mitoaggresomes,"(22) Fig. 2D). These
results led us to check whether AMBRA1CT, in combination
with mito-BCL2, was sufficient to induce apoptosis in the
absence of any specific death stimuli, such as STS. To this end,
we cotransfected HEK293 cells with AMBRA1CT and mito-
BCL2, and counted pyknotic nuclei in transfected cells, 24 h
and 48 h after transfection. As shown in Fig. 2E, 24 h post-
transfection more than 60% cells underwent death. Forty-eight
h after transfection, we observed up to 100% of apoptosis in
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Figure 1. AMBRA1 becomes proapoptotic in combination with mito-BCL2. (A) HEK293 cells were transfected with an empty vector or vectors encoding AMBRA1, mito-
BCL2 or cotransfected with both AMBRA1 and mito-BCL2. Twenty-four h after transfection, cells were treated or not with 2 mM STS for 3 h and viable cells were estimated
using the MTS assay. Results are expressed as arbitrary unit (a.u). Each point represents the mean (§ SD) of triplicate wells from 3 independent experiments. Statistical
analysis was performed using the Student t test (P< 0.05) versus pcDNA3 and (#, P< 0.05) vs. mito-BCL2. (B) HEK293 cells were transfected with an empty vector or vec-
tors encoding AMBRA1, mito-BCL2 or either cotransfected with both AMBRA1 and mito-BCL2. Twenty-four h after transfection, cells were treated with or without 2 mM
STS for 3 h. After extraction of proteins, we performed a western blot analysis by using antibodies against PARP1, AMBRA1, BCL2 and against ACTB (as a loading control).
(C) HEK293 cells were cotransfected with an empty vector and mito-DsRED (in order to stain mitochondria) or with mito-DsRED and vectors encoding AMBRA1, mito-
BCL2 or cotransfected with both AMBRA1 and mito-BCL2. Cells were then treated with STS 2 mM during 4 h and stained using an anti-CYCS (green) antibody. Nuclei
were stained with DAPI 1mg/ml 20 min. Merge of the different fluorescence signals are illustrated. Scale bar: 8 mm. (D) Graphic of densitometry values of CYCS release,
expressed as mean fluorescence of individual cells, normalized to total cellular surface (F:A, n D 30 cells/groups).
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Figure 2. For figure legend, see next page.
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cells overexpressing both AMBRA1CT and mito-BCL2. These
results demonstrate that AMBRA1CT, in combination with
mito-BCL2, induces apoptosis.
At this point, to demonstrate that the C-terminal fragment
of AMBRA1 could become proapoptotic following cell death
signals, we decided to use a mutant of AMBRA1 resistant to
CASP cleavage (AMBRA1D482A). In fact, the AMBRA1D482A
mutant, carrying a single-point mutation (D482! A) was ini-
tially mutated in order to disrupt the predicted putative caspase
cleavage site.20 We overexpressed either a vector encoding
AMBRA1D482A or AMBRA1CT in HEK293 cells, and treated
them with STS to induce apoptosis. We next checked, by confo-
cal microscope, CYCS release from mitochondria. As shown in
Fig. 3A (top panels), AMBRA1D482A did not induce CYCS
release in normal condition. Also, following STS treatment, we
observed that cells overexpressing AMBRA1D482A were healthy,
with a still significant overlap of CYCS staining with mitochon-
dria, indicating an antiapoptotic activity of this mutant. By con-
trast, overexpression of AMBRA1CT is sufficient to induce, in
normal conditions, CYCS release from mitochondria (Fig. 3B,
top panels), and this release is also visible in cells treated with
STS (Fig. 3B, bottom panels). The graphic of Fig. 3C illustrates
quantification of CYCS release. Last, by performing a western
blot analysis, we observed that BAX activation, following STS
treatment, is reduced in cells overexpressing AMBRA1D482A
compared with cells overexpressing AMBRA1WT or
AMBRA1CT (Fig. 3D). Altogether, these results indicate that,
during apoptosis, AMBRA1 cleavage by CASP is fundamental
to support BAX activation.
This being the case, in contrast with cells overexpressing
AMBRA1CT, cells overexpressing AMBRA1D482A are expected
to be protected from cell death. We thus decided to monitor
cell death by counting pyknotic nuclei in transfected cells. As
shown in Fig. 3E, cells positive for AMBRA1D482A undergo cell
death to a lesser extent than to AMBRA1CT-transfected cells. In
fact, it has been demonstrated in another cell system that
AMBRA1D482A delays cell death by maintaining its proauto-
phagic activity.20 Our observation confirms that AMBRA1CT
favors apoptosis, whereas its mutant resistant to CASP cleavage
can partially prolong cell survival.
Next, we decided to investigate the molecular mechanism of
AMBRA1CT activity on BCL2. BCL2 is a member of the BCL2
protein family; this family shares a consensus sequence called
BH3 domain; often, proapoptotic members of this family regu-
late, through direct binding via their BH3 domain, other BH3-
containing proteins. We thus hypothesized that AMBRA1CT
could act on BCL2 as a BH3 protein. First, we used a well-
known BH3-mimetic, ABT-737, to test whether the interaction
between AMBRA1 and mito-BCL2 could occur through a BH3
domain. We thus treated HEK293 cells overexpressing MYC-
AMBRA1WT with 10 mM ABT-737 for 3 h. We next immuno-
precipitated AMBRA1 with an anti-MYC antibody. As shown
in Fig. 4A, mito-BCL2 is associated with AMBRA1 in normal
conditions, this binding being reduced by ABT-737. We next
examined in silico the AMBRA1 sequence and found that
AMBRA1 possesses, indeed, a putative BH3 motif in its C-ter-
minal region (1215LPEAGQLA1222, see Fig. 4B). Therefore, in
principle, AMBRA1 could bind BCL2 through this motif. As
expected, 2 point mutations of this putative BH3 domain
(AMBRA1BH3-AE, [L1215A and G1219E]) almost abolished the
interaction between MYC-AMBRA1WT and mito-BCL2
(Fig. 4A). These results indicate that AMBRA1 can interact
with mito-BCL2 through a previously unrevealed BH3 domain.
A quantification of the ratio between mito-BCL2 coimmuno-
preciptated on the quantity of precipitated AMBRA1 is
reported in the graph (Fig. 4B).
Finally, we investigated the effect of AMBRA1BH3-AE on apo-
ptosis induction. To this end, we performed a confocal micros-
copy analysis and checked for CYCS release from
mitochondria, upon STS treatment, in cells overexpressing
AMBRA1WT or AMBRA1BH3-AE. CYCS release was reduced in
cells overexpressing AMBRA1BH3-AE following STS treatment
(Fig. 5B and C). Again, we quantified apoptosis upon STS treat-
ment in cells overexpressing this novel mutant construct. As
shown in Fig. 5D, AMBRA1BH3-AE can delay apoptosis similarly
to AMBRA1D482A, confirming that the AMBRA1CT acts on
BCL2, through its BH3 domain, during apoptosis. Last, by per-
forming a western blot analysis using an antibody against acti-
vated BAX, we observed that cells overexpressing
AMBRA1BH3-AE exhibited a lower basal activation of BAX
when compared with AMBRA1CT (Fig. 5E). Also, the capability
of AMBRA1 fragments to bind BH3-domain-containing pro-
teins is further proved by their dynamic interactions with other
antiapoptotic members of the BH3 family, as shown in Fig. S4.
At this point, our data suggest that AMBRA1 can regulate
the antiapoptotic effect of BCL2 during apoptosis induction by
a direct binding of this protein through a BH3 motif. To
strengthen these results, we decided to render AMBRA1 pro-
tein both autophagy deficient and BCL2-binding deficient. To
this end, we performed 2 point mutations of the BH3 domain
on the cleaved form of AMBRA1, which is deficient for auto-
phagy activity (Pagliarini et al., and Fig. S5; AMBRA1CT-BH3-AE).
Figure 2. (See previous page). The C-terminal part of AMBRA1, resulting from CASP cleavage, interacts with BCL2 and increases cell death following STS treatment.
(A) 2 mg of HEK293 cell lysate, obtained from DMSO-treated cells (control cells) or staurosporine-treated cells, were injected onto a superose 6 HR 10/30 FPLC gel filtration
column. Proteins were collected in 500 ml fractions. Equal amounts of each fraction have been analyzed by western blot using antibodies against AMBRA1 and BCL2. To
control that the STS treatment was efficient, we analyzed PARP cleavage by using an antibody against PARP. (B) HEK293 cells were transfected with a vector encoding
MYC-AMBRA1WT or Flag-AMBRA1CT. Twenty-four h after transfection, cells were treated or not with STS (2 mM, 2 h). Protein extracts were immunoprecipitated using an
anti-MYC or anti-Flag antibodies. Purified complexes and corresponding total extracts were analyzed by western blot (WB) using anti-AMBRA1 and anti-BCL2 antibodies.
(C) HEK293 cells were cotransfected with a vector encoding mito-DsRED (to stain mitochondria) and a vector encoding MYC-AMBRA1WT or AMBRA1CT (lane 1) or in addi-
tion with a vector encoding mito-BCL2 (lane 2). Twenty-four h after transfection, cells were then stained using antibody anti-AMBRA1 (AMBRA1WT and AMBRA1CT, green).
Nuclei were stained with DAPI 1 mg/ml 20 min. The merging of the different fluorescence signals is illustrated. Scale bar: 8 mm. (D) HEK293 cells were cotransfected with
a vector encoding AMBRA1CT and a vector encoding mito-BCL2. Forty-eight h after transfection, cells were fixed and stained using anti-AMBRA1 antibody (AMBRA1CT,
red). Nuclei were stained with DAPI 1mg/ml 20 min. The merging of the different fluorescence signals is illustrated. Scale bar: 8 mm. (E) HEK293 cells were cotransfected
with a vector encoding Flag-AMBRA1CT and a vector encoding mito-BCL2. Twenty-four or 48 h following transfection, cells were fixed and assessed by immunolabelling
using anti-Flag antibody and cells with condensed or fragmented nuclei were scored as pyknotic. Results are expressed as the percentage of transfected cells displaying
pyknotic nuclei. For each condition, transfected cells were counted in 10 random fields from 3 independent experiments. Values are given as a percentage (§ SD) of cell
death.
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Figure 3. The C-terminal part of AMBRA1 functions upstream of MOMP. (A) HEK293 cells were cotransfected with a vector encoding AMBRA1D482A and mito-DsRED (in
order to stain mitochondria) or (B) with mito-DsRED and vectors encoding AMBRA1CT. Twenty-four h after transfection, cells were treated with or without STS (2 mM) for
4 h. Cells were fixed and then stained using antibodies against CYCS (green) and against AMBRA1 (blue staining) that recognize only the overexpressed form of the pro-
tein. Nuclei were stained with DAPI 1mg/ml 20 min. The merging of the different fluorescence signals is illustrated. Scale bar: 8 mm. (C) Graphic of densitometric values
of CYCS release, expressed as mean fluorescence of individual cells, normalized to total cellular surface (F:A, nD30 cells/groups). (D) HEK293 cells were transfected with
vectors encoding AMBRA1WT, AMBRA1D482A or AMBRA1CT. Twenty-four h after transfection, cells were treated with 2 mM STS for 2 h. After extraction of proteins, we per-
formed a western blot analysis using antibodies against AMBRA1, activated BAX, and total BAX (as a loading control). The band density ratio of activated BAX/total BAX
was analyzed in 3 independent experiments; each point value represents the mean § SD from 3 independent experiments. Statistical analysis was performed using the
Student t test (, P < 0.05). (E) HEK293 cells were transfected with an empty vector or with a vector encoding AMBRA1D482A or AMBRA1CT. Twenty-four h following trans-
fection, cells were treated with 2 mM STS for 2 h. Cells were next fixed and examined by immunolabelling using anti-AMBRA1 antibody and cells with condensed or frag-
mented nuclei were scored as pyknotic. Results are expressed as the percentage of transfected cells displaying pyknotic nuclei. For each condition, transfected cells were
counted in 10 random fields from 3 independent experiments. Values are given as a percentage (§ SD) of cell death.
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As expected, these mutations almost abolished the interaction
between AMBRA1CT and mito-BCL2 (Fig. 6A). A quantifica-
tion of the ratio between coimmunoprecipitated mito-BCL2
and cleaved-AMBRA1 is reported in the graph (Fig. 6B).
Further, by counting pyknotic nuclei in transfected cells, we
observed that AMBRA1CT-BH3-AE exhibits less apoptotic activ-
ity than AMBRA1CT (Fig. 6C). Also, by looking at CYCS
release (Fig. 6D), we found that AMBRA1CT-BH3-AE-positive
cells present less release of CYCS from mitochondria than
cells overexpressing AMBRA1CT. Altogether these results sug-
gest that AMBRA1CT-BH3-AE induces less mitochondrial per-
meabilization than AMBRA1CT. Indeed, by monitoring BAX
translocation from cytosol to mitochondria, we found that
cells overexpressing AMBRA1CT-BH3-AE present less translo-
cated BAX on mitochondria than cells overexpressing
AMBRA1CT (Fig. 6F).
In conclusion, our data clearly indicate that AMBRA1 can
regulate the antiapoptotic effect of BCL2 during apoptosis
induction, by direct binding of this protein through a BH3
motif. A proposed working model for AMBRA1 in apoptosis is
finally shown in Fig. 7.
Discussion
Our results indicate that AMBRA1, in addition to its roles in
macroautophagy and mitophagy (reviewed in ref. 23), can act
as a positive mediator of mitochondrial apoptosis. We propose
here that the C-terminal part of AMBRA1, AMBRA1CT, gener-
ated by CASP cleavage, inactivates the BCL2 antiapoptotic fac-
tor, by a direct binding through its BH3-like domain. This
work demonstrates the existence of a reciprocal regulation
between AMBRA1 and BCL2 at the mitochondria.
The functional deficiency of Ambra1 in mice induces a
large number of supernumerary apoptotic cells in several
areas of the nervous system.1 Pagliarini et al.20 have demon-
strated that reduced levels of AMBRA1 in several cell lines
lead to increased susceptibility to different apoptotic stimuli.
Altogether, these results underline a prosurvival effect of
AMBRA1; in line with these results, we demonstrated that
cerebellar granule neurons overexpressing AMBRA1 are
more resistant to trophic factor withdrawal than control
neurons.7 Similarly to other proautophagic factors, such as
ATG5 and ATG12,16,21 AMBRA1 is cleaved during apopto-
sis, in order to abolish its prosurvival effect. Since a mutant
form of AMBRA1 resistant to CASP cleavage increases
resistance to cell death by blocking both BAX activation
and CYCS release from mitochondria, it can be postulated
that AMBRA1 cleavage is involved in mitochondrial outer
membrane permeabilization (MOMP). However, mutation
of the AMBRA1 CASP cleavage site does not completely
protect cells against cell death. This result can be explained
by the fact that, in addition to CASP cleavage, AMBRA1
(or its cleaved fragments) may also be subjected to CAPN
(calpain) cleavage, this leading to a complete destruction of
the protein. In addition, other proautophagic proteins, and
thus other prosurvival proteins, such as BECN1, are also
cleaved during cell death, contributing to cell death induc-
tion. The fact that AMBRA1 requires to be cleaved in order
to inhibit BCL2 opens the question about why the full-
length form is not able to have such an effect. It is well
possible that the N-terminal part of the protein, by binding
other proteins, induces a particular conformation that
blocks its inhibitory action on BCL2. This hypothesis is
supported by the fact that AMBRA1 can dynamically binds
the antiapoptotic proteins MCL1 and BCL2L1/BCLX. In
particular, the cleaved form of AMBRA1 binds preferen-
tially these antiapoptotic proteins when compared to full-
length AMBRA1 during cell death. These data suggest that
a conformational change of AMBRA1, that occurs during
cell death, is necessary to allow its binding with antiapop-
totic factors of the BCL2 family. Most likely, in addition to
BCL2, in order to potentiate cell death, AMBRA1CT could
also act on MCL1 and BCL2L1. Interestingly, no binding
can be found between AMBRA1 and the proapoptotic
members of the BCL2 family proteins, such as BAX and
BAK1/BAK.
BCL2 binds BECN1 on its BH3 domain. We show here that
also AMBRA1 contains a BH3-like motif along its sequence. Of
note, AMBRA1BH3-AE partially loses its binding with mito-
BCL2. In fact, we previously have proved that AMBRA1 binds
dynamically to the mitochondrial pool of BCL2 with both the
amino and the C-terminal domains of the protein. It is thus
possible that the resistant binding observed with mutant
AMBRA1BH3-AE is mediated by the N-terminal part of the pro-
tein. It will be interesting to identify the precise region of bind-
ing between AMBRA1 and BCL2 in this N-terminal region.
Figure 4. The C-terminal part of AMBRA1 interacts with mito-BCL2 via a BH3-like
motif. (A) HEK293 cells were transfected with a vector encoding MYC-AMBRA1WTor
MYC-AMBRA1BH3-AE. Twenty-four h after transfection, cells were treated with
DMSO (ctrl) or with ABT-737 during 3 h (10 mM). Total extracts were next immuno-
precipitated using an anti-MYC antibody. Purified complexes were analyzed by
western blot (WB) using anti-AMBRA1 and anti-BCL2 antibodies. (B) Identification
of a BH3-like motif within the AMBRA1 sequence. Point mutations of both an aro-
matic residue and the conserved residue are shown (AMBRA1BH3-AE [L1215A-
G1219E; APEAEQLA]). The band density ratio of immunoprecipitated AMBRA1 rela-
tive to immunoprecipitated BCL2 was analyzed in 3 independent experiments;
each point value represents the mean § SD from 3 independent experiments. Sta-
tistical analysis was performed using the Student t test (P < 0.05) versus the
DMSO condition.
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Human cancer grows by evading cell death. In fact, some
cancers, and in particular breast cancers, express high levels
of BCL2. Proteins from the BCL2 family are involved in
MOMP, a phenomenon mediating CYCS release from mito-
chondria (essential in cell death induction) and, for this
reason, MOMP is a good target in cancer therapy. Indeed,
BH3 mimetics are already used in chemotherapy and have
provided beneficial insights into the regulation of the
BCL2-BECN1 complex as well as in identifying additional
pathways involved in autophagic cell death. ABT-737 and
Figure 5. The mutant of AMBRA1 that cannot bind BCL2 loses its proapoptotic effect during cell death. (A) HEK293 cells were cotransfected with a vector encoding
AMBRA1WT or (B) AMBRA1BH3-AE and mito-DsRED (in order to stain mitochondria). Twenty-four h after transfection, cells were treated with or without STS (2 mM) for 4 h.
Cells were fixed and then stained using the anti-CYCS (green) antibody. Nuclei were stained with DAPI 1mg/ml 20 min. The merging of the different fluorescence signals
is illustrated. Scale bar: 8 mm. (C) HEK293 cells were transfected with an empty vector or with a vector encoding AMBRA1D482A, AMBRA1CT (see Fig. 3D) or with a vector
encoding AMBRA1BH3-AE. Twenty-four h following transfection, cells were treated with 2 mM STS during 3 h. Cells were next fixed and examined by immunolabelling
using anti-AMBRA1 antibody that recognizes only the overexpressed form of the protein and cells with condensed or fragmented nuclei were scored as pyknotic. Results
are expressed as the percentage of transfected cells displaying pyknotic nuclei. For each condition, transfected cells were counted in 10 random fields from 3 independent
experiments. Values are given as a percentage (§ SD) of cell death. (D) Graphic of densitometric values of CYCS release, expressed as mean fluorescence of individual
cells, normalized to total cellular surface (F:A, nD30 cells/groups). (E) HEK293 cells transfected with a vector encoding AMBRA1CT or AMBRA1BH3-AE were analyzed by west-
ern blot using antibodies against activated BAX and total BAX. The band density ratio of activated BAX/total BAX was analyzed in 3 independent experiments; each point
value represents the mean § SD from 3 independent experiments. Statistical analysis was performed using the Student t test (P < 0.05).
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Figure 6. For figure legend, see next page.
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HA14-1 also stimulate other proautophagic pathways and
hence activate the nutrient sensors SIRT1 (sirtuin 1) and
AMPK, inhibit MTOR, deplete cytoplasmic TP53/p53, and
trigger the CHUCK/IKKa and IKBKB/IKKb kinases.24 Here
we propose a novel mechanism of action of ABT-737,
which disrupts the interaction between AMBRA1 and mito-
BCL2, thus contributing to autophagy induction. Conse-
quently, exploiting the AMBRA1-BCL2 interaction could be
used to develop novel anticancer therapies.
BCL2 is upregulated in human breast cancers and medi-
ates the resistance of these cancers to chemotherapeutic
strategies,25,26 while, by contrast, AMBRA1 is an haploinsuf-
ficient tumor suppressor gene;27 given both these factors,
modulating the reciprocal AMBRA1 and BCL2 levels in
cancer cells by targeting their interaction could contribute
to early diagnosis and to predicting prognosis for breast
cancer.
Further studies are needed to discover binding partners
that can alter the reciprocal affinity of BCL2 and AMBRA1
at the mitochondria. It should also be interesting to investi-
gate whether post-translational modifications on AMBRA1
(such as its phosphorylation by kinases) regulate this
binding. Developing combination therapies between BH3
mimetics and kinase activators could provide a powerful
“double effect” on the AMBRA1-BCL2 complex. In conclu-
sion, identification of the mechanisms that maintain or dis-
rupt this complex may allow us to develop additional drugs
that can target it, thus ensuring an improved therapeutic
outcome.
Materials and methods
Antibodies
Mouse monoclonal anti-ACTB/b actin (Sigma-Aldrich,
A2228), monoclonal anti-BCL2 (Santa Cruz Biotechnology, sc-
7382), polyclonal anti-AMBRA1 (Novus, 26190002), monoclo-
nal anti-AMBRA1 (Santa Cruz Biotechnology, sc-398204),
mouse monoclonal anti-CYCS (Assay designs-Enzo Life Scien-
ces, 6H2-B4), polyclonal anti-LC3 (Cell Signaling Technology,
2775), monoclonal anti-SQSTM1/p62 (Santa Cruz Biotechnol-
ogy, sc-28369), polyclonal anti-activated BAX (6A7; Abcam
5714), polyclonal anti-BAX (Santa Cruz Biotechnology, sc-493,
N-20), polyclonal anti-PARP1 (Cell Signaling Technology,
9542), goat anti-BAK1 (G-23; Santa Cruz Biotechnology, sc-
832), mouse monoclonal anti-MYC (9E10; Santa Cruz Biotech-
nology, sc-4), mouse monoclonal anti-Flag (Sigma-Aldrich,
F3165), rabbit polyclonal anti-SOD2/MnSOD (Enzo Life Scien-
ces, 110F) and mouse monoclonal anti-TUBB/b tubulin
(Sigma-Aldrich, T9026).
Cloning and plasmids
Construct coding for AMBRA1WT, AMBRA1D482A and
AMBRA1CT (483-1300 amino acids) was cloned in pLPCX vec-
tor (Clontech, 631511).18
The construct coding for “mito-BCL2,” a mitochondrial-tar-
geted BCL2 in which the Cterminal hydrophobic sequence of
BCL2 is exchanged for an equivalent sequence from modified
ActA (Listeria monocytogenes actin assembly-inducing protein)
which binds specifically to the cytoplasmic face of mitochon-
drial outer membranes, was kindly provided by Beth Levine9
and was cloned in prcCMV vector.
The mito-DsRED construct encodes for human Cox8A
mitochondria signal which is fused with wild-type-DsRED in
pcDNA3 vector (Invitrogen).
We summarized in the table all constructs used in the
present work:
Figure 6. (See previous page). The mutant form of cleaved AMBRA1 that cannot bind BCL2 loses its proapoptotic effect during cell death. (A) HEK293 cells were trans-
fected with a vector encoding Flag-AMBRA1CT or Flag-AMBRA1CT-BH3-AE. Twenty-four h after transfection, total extracts were next immunoprecipitated using an anti-Flag
antibody. Purified complexes were analyzed by western blot (WB) using anti-AMBRA1 and anti-BCL2 antibodies. (B) The band density ratio of immunoprecipitated
AMBRA1 relative to immunoprecipitated BCL2 was analyzed in 3 independent experiments; each point value represents the mean§ SD from 3 independent experiments.
Statistical analysis was performed using the Student t test (, P< 0.05) vs. CT. (C) HEK293 cells were transfected with a vector encoding Flag-AMBRA1CT or Flag-AMBRA1CT-
BH3-AE. Twenty-four h following transfection, cells were treated with 2 mM STS during 2 h. Cells were next fixed and examined by immunolabelling using anti-AMBRA1
antibody that recognizes only the overexpressed form of the protein and cells with condensed or fragmented nuclei were scored as pyknotic. Results are expressed as
the percentage of transfected cells displaying pyknotic nuclei. For each condition, transfected cells were counted in 10 random fields from 3 independent experiments.
Values are given as a percentage (§ SD) of cell death. (D) HEK293 cells were cotransfected with a vector encoding Flag-AMBRA1CT or Flag-AMBRA1CT-BH3-AE and mito-
DsRED (in order to stain mitochondria). Cells were then treated with STS 2 mM during 4 h and stained using an anti-CYCS antibody (green). Nuclei were stained with
DAPI 1mg/ml during 20 min. The merging of the different fluorescence signals is illustrated. Scale bar: 8 mm. (E) Graphic of densitometric values of CYCS release,
expressed as mean fluorescence of individual cells, normalized to total cellular surface (F:A, nD30 cells/groups). (F) HEK293 cells were transfected with a vector encoding
Flag-AMBRA1CT or Flag-AMBRA1CT-BH3-AE. Twenty-four h after transfection, cytosolic and mitochondrial fractions were analyzed by western blot (WB) using anti-BAX and
anti-SOD2 antibodies. The band density ratio of translocated BAX on mitochondria was analyzed in 3 independent experiments; each point value represents the mean §
SD from 3 independent experiments. Statistical analysis was performed using the Student t test (, P < 0.01) versus CT.
Figure 7. The proposed working model for AMBRA1 in mitochondrial apoptosis.
Upon induction of apoptosis, AMBRA1 is subjected to CASP cleavage. In the initial
phase of apoptosis, the C-terminal fragment of AMBRA1 is stable and interacts
directly with BCL2 through its BH3-like domain, thus likely increasing cell death
(cell death amplification loop).
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Point mutations were generated using the QuickChange site-
directed mutagenesis kit (Stratagene, 200519) and all plasmid
constructs made in this study were verified by DNA sequencing
(Eurofins). The oligonucleotides used for mutagenesis, PCR,
and DNA sequencing were purchased from Invitrogen.
Cell cultures
The human embryonic kidney HEK293 cells and HeLa cells
were cultured in Dulbecco’s modified Eagle’s medium (Lonza,
BE12-604F) supplemented with 10% FBS (Gibco; Thermo
Fisher Scientific, 10270-106) , and 1% penicillin-streptomycin
solution (Lonza, 17-602 E) at 37C under 5% CO2.
Cell culture transfection
Transient transfections of expression plasmids into HEK293
cells were performed using TurboFect according to the suppli-
er’s instructions (Thermo Fisher Scientific, R0532).
Determination of cell viability
Cell survival was estimated by using the MTS assay or by
counting the number of condensed or fragmented nuclei as
observed using DAPI (Sigma Aldrich, D9542) staining. The tet-
razolium salt MTS (3-[4,5-dimethyl-2-thiazolyl]-2-5diphenyl-
2H tratrazolium bromide; Sigma Aldrich, M2128) was added to
cell cultures (1 mg/ml) and incubated for 30 min a 37C. Cells
were then lysed in DMSO (Sigma Aldrich, 472301). Formazan
production by living cells was assessed by measuring absor-
bance at 540 nm using a Biotek Elx-800 microplate reader
(Mandel Scientific Inc.) For cell counting, cultures were fixed
in 4% paraformaldehyde (Merck Millipore, 104005) in PBS
(UCS Diagnostic, PBS1199) for 10 min at 4C and stained with
DAPI in PBS for 20 min at room temperature. Cells were
washed 3 times with PBS, then mounted and observed under a
ZEISS confocal laser microscope (CLSM700; Jena, Germany).
For each condition, random images were captured and ana-
lyzed using Zen Light edition software. Cell viability was then
scored on the basis of nuclear morphology: cells containing
condensed or fragmented nuclei were counted as dying or dead
cells.
Immunocytochemistry
Cells were washed in PBS and fixed with 4% paraformaldehyde
in PBS for 15 min. After permeabilization with 0.4% Triton X-
100 (Sigma Aldrich, X100) in PBS for 5 min, cells were blocked
in 3% normal goat serum (Sigma-Aldrich, G9023) in PBS and
incubated overnight at 4 degrees with primary antibodies. We
used the antibodies directed against AMBRA1 and CYCS. Cells
were then washed in blocking buffer and incubated for 1 h with
labeled anti-mouse (Alexa Fluor 488; Thermo Fisher Scientific,
A11017) or anti-rabbit (CyTM3; Jackson ImmunoResearch,
115-165-166) secondary antibodies. Nuclei were stained with
1 mg/ml DAPI and examined under a Zeiss LSM 700 100x oil-
immersion objective (CLSM700; Jena, Germany). We used
“ZEN 2009 Light edition” software for image analysis. All
acquisitions were performed in non-saturated single z-confocal
planes.
Western blot analysis
Cell extracts were centrifuged at 13,000 g for 10 min at 4C.
Protein concentrations were determined with the Bio-Rad Pro-
tein Assay Kit (Bio-Rad, 5000001). Cell extracts or immunopre-
cipitates were separated by SDS-PAGE and transferred onto
nylon membranes (Immobilon P; Merck-Millipore,
IPFL10100). Membranes were incubated with primary antibod-
ies followed by horseradish peroxidase-conjugate secondary
antibody (Bio-Rad, 1706515 and 1721011) and visualized with
ECL (Merck-Millipore WBKLS0500).
Immunoprecipitation
Cells were lysed in RIPA buffer plus protease inhibitor cocktail
(Sigma Aldrich, P8340). Equal amounts of protein (500 mg)
were incubated with 2 ml of monoclonal anti-MYC antibody
for 4 h followed by 60 min incubation with 30 ml of protein A
Constructs Type of mutation Feature
Flag-tagged-
AMBRA1D482A
Single-point mutation (D482
! A) on the predicted
caspase cleavage site of
AMBRA1
This mutant of AMBRA1 is
uncleavable by
caspases following
apoptosis induction
and maintains its
proautophagic activity
MYC-tagged-
AMBRA1WT
No mutation This construct encodes for
the wild-type form of
AMBRA1
MYC-tagged-
AMBRA1BH3-AE
Two-point mutations in the
BH3 domain of AMBRA1
L1215! A and G1219
! E
This mutant of AMBRA1
partially loses its
binding with mito-BCL2
protein
Flag-tagged-
AMBRA1CT
Terminal fragment of AMBRA1
resulting from caspase
cleavage (483-1300 amino
acids)
This construct encodes for
the C-terminal part of
AMBRA1 resulting
fronm caspase
cleavage. This fragment
binds mito-BCL2
Flag-tagged-
AMBRA1CT-BH3-AE
Two-point mutations in the
BH3 domain of the C-
terminal fragment of
AMBRA1L1215! A and
G1219! E resulting from
caspase cleavage (483-1300
amino acids)
This construct encodes a C-
terminal fragment of
AMBRA1 which partially
loses its binding with
mito-BCL2
Mito-BCL2 The mitochondrial-targeted
BCL2 presents the C-
terminal hydrophobic
sequence of BCL2
exchanged for an
equivalent sequence from
modified ActA (Listeria
monocytogenes Actin
assembly-inducing protein),
which binds specifically to
the cytoplasmic face of
mitochondrial outer
membranes. In this case
BCL2 is fused with ActA
sequence.
This construct encodes a
BCL2 protein that it is
specifically targeted to
the mitochondria
where it acts as an
antiapoptotic factor.
Mito-DsRED Human Cox8A mitochondria
signal is fused with wild-
type-DsRED protein in
pcDNA3 vector.
This construct encodes for
a red protein that is
targeted to the
mitochondria. It is used
in microscopy analysis
in order to stain the
mitochondria network.
AUTOPHAGY 973
agarose beads (Roche, 11719408001). The beads were collected
by centrifugation and washed 4 times with the RIPA buffer.
Proteins bound to the beads were eluted with 30 ml of SDS-
polyacrylamide gel electrophoresis sample buffer and heated to
95C for 10 min.
Mitochondria/cytosol purification
Mitochondria and cytosol purification occurs by standard dif-
ferential centrifugations. HEK293 cells were suspended in
homogenization buffer (0.25 M sucrose, 10 mM HEPES, pH 7,
1 mM EDTA [Sigma-Aldrich, S0389, H4034, and ED-100,
respectively]) with protease and phosphatase inhibitors. Mito-
chondria suspensions were obtained homogenizing the solution
with 40–60 pulses (one pulse corresponds to approximately
one sec), in vertical movements. After homogenization, the sus-
pension was centrifuged at 11 000 g for 15 min at 4C. The
mitochondrial pellet fraction was suspended in isolation buffer
(0.2 M sucrose, 10 mM Tris-MOPS [Sigma, M1254], pH 7.4,
0.1 mM EGTA-Tris [Sigma Aldrich, E4378]). The supernatant
fraction corresponded to soluble cytosolic proteins.
Size-exclusion fast protein liquid chromatography
(sec-FPLC)
Two milligrams of HEK293 cell lysate, obtained from DMSO-
treated cells or staurosporine-treated cells, were injected onto a
Superose 6 HR 10/30 fast protein liquid chromatography
(FPLC) gel filtration column (Amersham Pharmacia Bioscien-
ces, 17-0537-01) connected to a Pharmacia LKB LCC 501 Plus
FPLC System (Amersham Pharmacia LKB Biotechnologies,
Piscataway, N.J.). Lysate preparation and column equilibration
have been previously described.5 CAPN (calpain II inhibitor,
50 mM; Sigma-Aldrich, A6060) and CASP (Q-VD-OPH, 100
mM; Santa Cruz Biotechnology, sc-222230) inhibitors were
added in the lysis buffer in order to prevent AMBRA1 cleavage
during the fraction separation. Proteins were collected in
500 ml fractions, precipitated with 10% trichloroacetic acid,
and resolved in SDS-PAGE for western blot analyses. Gel filtra-
tion column was calibrated as previously described.25 Equal
amounts of each fraction were analyzed by western blot.
Quantification of CYCS release
Quantification of CYCS release from mitochondria was
performed on transfected cells by densitometric analyses, as
previously described.28 After background subtraction, CYCS
cell-associated signals were quantified by manually outlining
individual cells and measuring cell-associated fluorescence
intensity with the ImageJ software (http://rsb.info.nih.gov/ij/).
The F:A ratio defines mean fluorescence of individual cells (F)
normalized to total cellular surface (A).
Statistical analyses
Statistical analyses were performed using the Student 2-tailed
ttest. Data were shown as means § SD of 3 independent experi-
ments. Values of p < 0,05 were considered significant.
Abbreviations
AMBRA1 autophagy/Beclin 1 regulator 1
AMBRA1BH3-AE autophagy/Beclin 1 regulator 1, mutated
in BH3 motif
AMBRA1CT C-terminal part of AMBRA1
AMBRA1CT-BH3-AE C-terminal part of AMBRA1, mutated in
BH3 motif
BAX BCL2-associated X protein
BCL2 B-cell CLL/lymphoma 2
BECN1 Beclin 1, autophagy related
BH3 BCL2 homology domain 3
CASP caspase
CYCS cytochrome c, somatic
FPLC fast protein liquid chromatography
HEK293 human embryonic kidney
MOMP mitochondrial outer membrane
permeabilization
Mito-BCL2 mitochondrial targeted BCL2
PARK2 parkin RBR E3 ubiquitin protein ligase
STS staurosporin
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